Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Next Previous
Trial Profile

Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Scopolamine (Primary)
  • Indications Motion sickness
  • Focus Therapeutic Use
  • Sponsors Repurposed Therapeutics

Most Recent Events

  • 24 Oct 2023 According to a Defender Pharmaceuticals media release, this trial is conducted in collaboration with investigators from the United States National Aeronautics and Space Administration (NASA). Enrollment will start as soon as possible and results are expected in second quarter 2024.
  • 06 Jun 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top